Abstract
BT-11 is an orally active, gut-restricted investigational therapeutic targeting the lanthionine synthetase C-like 2 pathway with lead indications in ulcerative colitis (UC) and Crohn disease (CD), 2 manifestations of inflammatory bowel disease (IBD). In 5 mouse models of IBD, BT-11 is effective at oral doses of 8 mg/kg. BT-11 was also efficacious at nanomolar concentrations in primary human samples from patients with UC and CD. BT-11 was tested under Good Laboratory Practice conditions in 90-day repeat-dose general toxicity studies in rats and dogs, toxicokinetics, respiratory, cardiovascular and central nervous system safety pharmacology, and genotoxicity studies. Oral BT-11 did not cause any clinical signs of toxicity, biochemical or hematological changes, or macroscopic or microscopic changes to organs in 90-day repeat-dose toxicity studies in rats and dogs at doses up to 1,000 mg/kg/d. Oral BT-11 resulted in low systemic exposure in both rats (area under the curve exposure from t = 0 to t = 8 hours [AUC0-8] of 216 h × ng/mL) and dogs (650 h × ng/mL) and rapid clearance with an average half-life of 3 hours. BT-11 did not induce changes in respiratory function, electrocardiogram parameters, or behavior with single oral doses ...Continue Reading
References
Dec 1, 1975·Mutation Research·B N AmesE Yamasaki
Feb 1, 1976·Mutation Research·M H Green, W J Muriel
Jun 1, 1977·Toxicology and Applied Pharmacology·P M Edwards, V H Parker
Jul 1, 1990·Mutation Research·K H MavourninJ A Heddle
Mar 1, 1989·Gut·A Sonnenberg
Aug 1, 1988·Fundamental and Applied Toxicology : Official Journal of the Society of Toxicology·V C MoserR C MacPhail
May 1, 1973·Mutation Research·J A Heddle
Jun 1, 1974·European Journal of Pharmacology·S I Ankier
Sep 1, 1981·Mutation Research·R J PrestonJ S Wassom
Jun 1, 1994·Mutation Research·M HayashiH Shimada
Nov 28, 2002·Experimental Animals·Hiroyasu Miyazaki, Masahiro Tagawa
Sep 27, 2006·Clinical Nutrition : Official Journal of the European Society of Parenteral and Enteral Nutrition·Amir J GuriJosep Bassaganya-Riera
Feb 1, 2004·Clinics in Colon and Rectal Surgery·Uma Mahadevan
Aug 24, 2012·Lancet·Daniel C Baumgart, William J Sandborn
Aug 24, 2012·Lancet·Ingrid OrdásWilliam J Sandborn
Sep 24, 2014·Inflammatory Bowel Diseases·Anna-Maria GlobigBertram Bengsch
May 28, 2016·International Journal of Toxicology·Philippe BisselJosep Bassaganya-Riera
Dec 10, 2016·Journal of Medicinal Chemistry·Adria CarboJosep Bassaganya-Riera
Mar 9, 2017·Frontiers in Immunology·Andrew LeberRaquel Hontecillas
Jun 16, 2017·Expert Review of Clinical Immunology·Julian Panés, Ignacio Alfaro
Jul 1, 2017·Frontiers in Nutrition·Elena ZocchiJosep Bassaganya-Riera
Aug 3, 2017·Artificial Intelligence in Medicine·Andrew LeberJosep Bassaganya-Riera
May 3, 2018·Inflammatory Bowel Diseases·Andrew LeberJosep Bassaganya-Riera
Citations
May 12, 2019·Inflammatory Bowel Diseases·Andrew LeberJosep Bassaganya-Riera
Jun 2, 2020·Oncotarget·Sridhar Mani
Oct 28, 2019·Drug and Chemical Toxicology·Andrew LeberJosep Bassaganya-Riera
Mar 6, 2021·Frontiers in Nutrition·Josep Bassaganya-RieraMauro Serafini
Oct 8, 2021·Scientific Reports·Nuria Tubau-JuniJosep Bassaganya-Riera